Pfizer's $16.6 billion quarter had nearly flat sales, while reported profit per share fell 9% year over year.
Pfizer reported $16.6B in Q3 2026 revenues, flat year-over-year. Excluding COVID-related products, revenues grew 7%, with launched and acquired products up 32%. EPS fell 9% to $0.56. The company raised 2026 guidance, targeting $62.0-$64.0B in revenue and $2.95-$3.05 in adjusted EPS. Pfizer highlighted progress in obesity, oncology, and immunology programs.
How this was made
The 30-second read
Why it matters
The raised guidance could drive short‑term buying, but flat sales and EPS drop may temper enthusiasm.
Market read
Primary earnings release for a mega‑cap pharma, likely to move the stock on guidance lift.
What to watch
Potential headwinds from COVID product declines and foreign exchange impacts.
Background
Pfizer's Q3 2026 earnings press release with operational revenue growth in non‑COVID products and a one‑time R&D charge.
Ticker impact
Pfizer reported Q3 2026 results with flat sales, EPS decline and raised full-year revenue and EPS guidance.
likely upward pressure as investors price in higher revenue outlook
Guidance lift of $1.5‑$62.0 B revenue and narrowed EPS range signals improved outlook, which typically supports the stock.
Market effects
Strengthens biotech/pharma sector outlook with higher guidance.
U.S. market may see modest rally in healthcare stocks.
Limited to investors tracking large-cap pharma earnings.
Counterpoint
Guidance raise may be offset by flat sales and EPS decline, suggesting margin pressure.
Key entities
- ExecutiveAlbert Bourla
Pfizer CEO providing commentary on results.
- ExecutiveCecile Guegan
New CFO and EVP of Pfizer.
